Participants 104 122 3
metabolic syndrome
Participants 150 400 4
we tested in patients with metabolic syndrome whether allopurinol through decreasing oxidative stress improves endothelial function, and ameliorates inflammatory state represented by markers of myeloperoxidase, C-reactive protein (CRP) and fibrinogen
Participants 449 554 9
subjects with metabolic syndrome were treated with allopurinol (n = 28) or placebo (n = 22) for one month
Participants 1578 1610 3
patients with metabolic syndrome
